Introduction:
Generalized lymphadenopathy is commonly attributed to infectious causes such as human immunodeficiency virus (HIV) infection, Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), human herpesvirus 6 (HHV-6), tuberculosis (TB), syphilis, cat-scratch disease caused by Bartonella henselae, or other parasitic and fungal infections. Lymphadenopathy can also occur following recent immunization and is usually transient requiring no further workup. Ho et al described that less than 1.1% of individuals developed lymphadenopathy following coronavirus disease 2019 (COVID-19) vaccination lasting on average between 10 days to two months. It was often identified incidentally on computed tomography (CT) scans, routine screening mammography, or positron emission tomography scans, breast MRI, and ultrasounds. The most common site for COVID-19 vaccine-associated lymphadenopathy is usually axillary followed by supraclavicular and cervical lymphadenopathy. [1] In the following report, we present a rare case of metastatic prostate cancer diagnosed after initially presenting as generalized lymphadenopathy following a COVID booster vaccination.